论文部分内容阅读
目的:研究中重度支气管哮喘患者应用布地奈德福莫特罗和噻托溴铵治疗的有效性及安全性。方法:将我院收治的98例中重度支气管哮喘患者随机分为两组,各49例,对照组应用布地奈德福莫特罗治疗,研究组联合应用布地奈德福莫特罗和噻托溴铵,比较两组的治疗效果、肺功能改善情况、生活质量变化等。结果:研究组治疗后的哮喘控制测试(ACT)评分显著高于对照组,圣乔治呼吸疾病问卷(SGRO)评分显著低于对照组,差异有统计学意义(P<0.05);治疗后两组的各项指标均有明显改善,研究组的免疫球蛋白E(IgE)、嗜酸粒细胞计数(EOS)均显著低于对照组,1秒用力肺活量(FEV_1)、用力呼气中期流速(FEF)、最大呼气峰流速(PEF)值均显著高于对照组,差异有统计学意义(P<0.05);研究组的治愈率、总有效率分别为48.98%、81.63%,与对照组的32.65%、63.27%相比,差异均有统计学意义(P<0.05)。结论:中重度支气管哮喘患者应用布地奈德福莫特罗和噻托溴铵进行治疗,能够较好地控制哮喘发作,缓解临床症状,提高患者的生活质量。
Objective: To study the efficacy and safety of budesonide formoterol and tiotropium in patients with moderate-severe bronchial asthma. Methods: A total of 98 patients with moderate-to-severe bronchial asthma admitted to our hospital were randomly divided into two groups (n = 49 each). The control group was treated with budesonide formoterol. The study group was given budesonide combined with formoterol Bromonium bromide, compared the two groups of treatment, pulmonary function improvement, quality of life changes. Results: The ACT score of the study group was significantly higher than that of the control group, and the score of SGRO was significantly lower than that of the control group (P <0.05). After treatment, the two groups (IgE) and eosinophil count (EOS) of the study group were significantly lower than those of the control group, forced vital capacity at 1 second (FEV 1), forced expiratory mid-term flow rate (FEF ), Maximum expiratory peak flow velocity (PEF) were significantly higher than the control group, the difference was statistically significant (P <0.05); the cure rate of the study group, the total effective rate was 48.98%, 81.63% 32.65%, 63.27%, the difference was statistically significant (P <0.05). Conclusion: Moderate and severe bronchial asthma patients treated with budesonide formoterol and tiotropium can better control asthma attacks, relieve clinical symptoms and improve the quality of life of patients.